Table 1. Clinical feature of refractory pituitary adenomas.
| Case | Sex | age (y) | PA | Invasive (Y or N) |
Ki-67 (%) | growth rate(%/m) | Atypical (Y or N) |
Surgery (n) |
RT | TMZ (cycles) |
Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 46 | NFPA | Y | 40% | 2.7% | Y | 3 | GKS | 2 | Dead |
| 2 | M | 64 | ACTH | Y | 5% | 3.3% | Y | 1 | GKS | 6 | Dead |
| 3 | M | 46 | ACTH | Y | >10% | 2.6% | Y | 4 | Radiation | N | Dead |
| 4 | M | 75 | NFPA | Y | >3% | 4.2% | Y | 1 | N | 5 | Progression |
| 5 | F | 43 | ACTH | Y | >3% | 3.1% | N | 1 | Radiation | 6 | Progression |
| 6 | F | 29 | GH | Y | 3% | 2.3% | N | 2 | GKS | 2 | Progression |
| 7 | M | 50 | NFPA | Y | 40% | 2.8% | Y | 3 | GKS | 3 | Progression |
| 8 | F | 30 | NFPA | Y | >3% | 2.6% | N | 1 | N | 5 | Progression |
| 9 | M | 28 | NFPA | Y | 3% | 2.9% | Y | 4 | Radiation | 2 | Progression |
| 10 | F | 55 | PRL | Y | 10% | 3.3% | N | 1 | GKS | 6 | Progression |
| 11 | F | 66 | NFPA | Y | 5% | 4.6% | Y | 2 | N | 6 | Dead |
| 12 | M | 30 | NFPA | Y | >3% | 3.7% | Y | 2 | N | 2 | Progression |
GKS: gamma knife surgery; RT: radiotherapy; TMZ: temozolomide; N: no